Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Genotype-specific neoplastic risk profiles in patients with VHL disease
Ganner, Athina , Sekula, Peggy , Schiavi, Francesca , Joo, Julia H. , Sansó, Gabriela , Almeida, Madson Q. , Knoblauch, Anna Laura, Gizaw, Christine Julia, Krzystolik, Karol , Astheimer, Sophie, Vieites, Ana , Donegan, Diane , Simsir, Ilgin Yildirim , Bandgar, Tushar , Pawlaczek, Agnieszka, Zandee, Wouter T. , Kater, Cláudio E. , Qi, Xiao-Ping , Deutschbein, Timo , Dallagnol, Tabatha Nakakogue , Yukina, Marina, Baudrand, René , Andreescu, Corina , Kunavisarut, Tada , Ishak, Nur Diana Binte , Horn, Xavier Le Guillon, Shutler, Gemma, Jovanović, Milan , Calissendorf, Jan, Circosta, Francesco , Bugalho, Maria João , Corssmit, Eleonora Pm, Goldmann, Andrea , Zovato, Stefania , Santana, Lucas Santos de , Freitas-Castro, Felipe , Rothermund, Christy A, Zimmermann, Josa, Aycut, Ayca, Vroonen, Laurent , Krauß, Tobias , Taschner, Christian , Ruf, Juri , Gläsker, Sven , Bucher, Felicitas , Agostini, Hansjürgen , Jilg, Cordula A. , Schultze‐Seemann, Wolfgang, Bausch, Birke, Bergfeld, Antonia, Rhein, Kilian , Fang, Xu-Dong , Kotsis, Fruzsina , Schäfer, Tobias, Links, Thera P. , Makay, Özer , Fagundes, Gustavo Freitas Cardoso, Shah, Nalini , Barontini, Marta, Larsson, Catharina , Januszewicz, Andrzej , Lima, José Viana , Cybulski, Cezary, Walz, Martin K. , Koettgen, Anna, Neumann, Hartmut P.H., Neumann‐Haefelin, Elke , Köttgen, Anna , Yukina, M. Yu. , Sekula, Peggy , Almeida, Madson Q , Juhlin, Carl Christofer , Ngeow, Joanne , Eng, Charis , Baudrand, Rene , Ferrara, Alfonso Massimiliano , Steiert, Christine , Achatz, Maria Isabel , Hundsberger, Thomas , Lubiński, Jan , Hasse-Lazar, Kornelia , Yu, Kai , Rostomyan, Liliya , Remde, Hanna , Horn, Xavier Le Guillou , Jovanovic, Milan, Pęczkowska, Mariola , Calissendorff, Jan , Gimm, Oliver , Quinkler, Marcus , Watutantrige‐Fernando, Sara , Rothermundt, Christian Alexander , Zimmermann, Josa, Durmaz, Asude , Klingler, Jan‐Helge , Lang, Stefan Johann , Bergfeld, Antonia, Uslar, Thomas , Concistrè, Antonio , Juhlin, C. Christofer , Rocha, José Cláudio Casali da , Petramala, Luigi , Tsoy, U. A. , Grineva, Elena , Fagundes, Gustavo F C , Ngeow, Joanne , Opocher, Giuseppe , Wohllk, Nelson , Letizia, Claudio , Donatini, Gianluca , Maher, Eamonn R. , Beltsevich, D. G. , Bancos, Irina , Eng, Charis

Endocrine-Related Cancer | April 9, 2025 | Volume: 32 | Issue: 5 | Pages: No page available

10.1530/erc-24-0260 | PMID 40202835 Get It

Abstract Hereditary tumor predisposition syndromes pose a challenge for early detection and timely treatment of tumors. In von Hippel–Lindau disease, desirable personalized surveillance programs are lacking due to insufficient data on genotype-specific risk profiles of individual mutations. To describe neoplastic risk profiles for carriers of pathogenic and likely pathogenic VHL germline mutations, our observational study recruited 1,350 participants from 40 centers worldwide. 432 different VHL germline mutations were observed, with p.Asn78Ser, p.Arg161Ter, p.Arg161Gln, p.Arg167Gln, p.Arg167Trp and p.Tyr98His being the six most frequent, occurring in a total of 493 carriers (36.5%) and in ≥30 patients each. Age-related penetrance risks for retinal hemangioblastoma, central nervous system hemangioblastoma, renal cell carcinoma, pancreatic neuroendocrine tumors and pheochromocytoma/paraganglioma in carriers of the most frequent VHL mutations were assessed. In addition, the number of organs affected, the frequency of surgery and the outcome are reported. Pairwise comparisons of the age-dependent tumor penetrance of these six mutations showed that 47 out of 90 pairs were significantly different. The most significant associations were found in p.Tyr98His (n = 19), followed by p.Arg161Ter (n = 10). All pairwise comparisons of mutations affecting different codons showed at least one significant (P < 0.05) difference, except for p.Asn78Ser vs p.Arg161Ter. Thus, tumor risk varied by VHL mutation type and location, but did not differ between the truncating mutation p.Arg161Ter and the missense mutation p.Asn78Ser. Our study demonstrates the importance of mutation-specific phenotype prediction. With appropriate validation, the data have important implications for risk assessment and decision making in tumor prevention for carriers of the respective VHL mutations.
Change of Heart: Can Artificial Intelligence Transform Infective Endocarditis Management?
McHugh, Jack , Challener, Douglas W. , McHugh, Jack , Tabaja, Hussam , Challener, Douglas

Pathogens | April 9, 2025 | Volume: 14 | Issue: 4 | Pages: 371

10.3390/pathogens14040371 | PMID 40333137 Get It

Artificial intelligence (AI) has emerged as a promising adjunct in the diagnosis and management of infective endocarditis (IE), a disease characterized by diagnostic complexity and significant morbidity. Machine learning (ML) models such as SABIER and SYSUPMIE have demonstrated strong predictive accuracy for early IE diagnosis, embolic risk stratification, and postoperative mortality, surpassing traditional clinical scoring systems. In imaging, AI-enhanced echocardiography and advanced modalities like FDG-PET/CT offer improved sensitivity, specificity, and reduced inter-observer variability, potentially transforming clinical decision making. Additionally, AI-powered microbiological techniques, including MALDI-TOF mass spectrometry combined with ML and neural network-based metagenomic classifiers, show promise in rapidly identifying pathogens and predicting antimicrobial resistance. Despite encouraging early results, widespread adoption faces barriers, including data limitations, interpretability issues, ethical concerns, and the need for robust validation. Future directions include leveraging generative AI as clinical consultative tools, provided their capabilities and limitations are carefully managed. Ultimately, collaborative efforts addressing these challenges could transform IE care, enhancing diagnostic accuracy, clinical outcomes, and patient safety.
Single-cell bacterial culturing and antibiotic susceptibility testing using permeable hydrogel-shelled microcapsules
Pratt, Shawna L. , Williamson, Kerry S., Franklin, Michael J. , Chang, Connie B. , Chang, Connie B , Franklin, Michael J.

No container title available | April 9, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.04.03.647129 Get It

Abstract Microbial communities, such as biofilms, consist of bacteria that exhibit cell-to-cell heterogeneity in their physiological properties, including enzyme activity and gene expression. This single-cell heterogeneity influences the community’s overall metabolic activity and contributes to stress tolerance, such as antimicrobial resistance. To study the impact of single-cell heterogeneity on population-level behaviors, methods have been developed to isolate and characterize bacteria at the single-cell level. One such method includes water-in-oil drop-based microfluidics. However, a limitation of this approach is that the droplet contents cannot be exchanged during experiments, making it difficult to investigate how cells respond to changing environmental conditions. To address this limitation, we developed a drop-based microfluidic technique called Bioflex, which creates permeable hydrogel-shell microcapsules that act as growth chambers for individual bacterial cells. The microcapsules are formed by crosslinking a shell made from a PEG-based hydrogel (4-arm PEG-maleimide) around a dextran core. After cross-linking, the dextran core diffuses out of the capsules and is replaced with buffer or growth medium. By adjusting fluid flow rates during the process, we can control the size and shell thickness of the microcapsules, allowing the production of different capsule architectures. The Bioflex capsules are biocompatible, supporting the encapsulation and growth of Pseudomonas aeruginosa by allowing nutrient transport across the capsule shell. Moreover, the capsules remained permeable to antimicrobial treatments introduced during P. aeruginosa incubation. For example, P. aeruginosa cells in Bioflex capsules responded to externally delivered ciprofloxacin treatments, with their responses varying depending on the timing of the antibiotic introduction. In summary, Bioflex capsules provide a novel, high-throughput platform for isolating single-cells and testing how single-cell derived communities react to time-dependent stresses, such as antibiotic treatments. Graphical Abstract Bacterial cultivation using permeable microscale Bioflex capsules. (A) P. aeruginosa PAO1 expressing eGFP cultured in a Bioflex capsule starting from a single cell. (B) Bioflex capsules are permeable to nutrient and waste transport. (C) The capsules allow for exchange of media to study the responses of single cells or small populations of cells within the drops using time-lapse imaging.
Help Us to Help You: Recommendations for Continued Enforcement Discretion for Common Infectious Disease Test Modifications under the FDA Final Rule
Rodino, Kyle G. , Graf, Erin H. , Graf, Erin H , Larkin, Paige M. K.

Clinical Chemistry | April 9, 2025 | Volume: 71 | Issue: 5 | Pages: 538-541

10.1093/clinchem/hvaf018 | PMID 40238134 Get It

Antimicrobial-induced neutropenia in patients receiving OPAT or COpAT: A large multisite retrospective cohort study
Abel, A. L. , Saleh, Omar Abu , Cole, Kristin, Jensen, Kelsey , Martin, Peter , Pertzborn, Margaret , Virk, Abinash , Mara, Kristin C. , Edwards, Megan , Van Abel, Amy, Abu Saleh, Omar , Challener, Doug, Jensen, Kelsey , Mara, Kristin C , Edwards, Megan, Challener, Douglas W. , Rivera, Christina G.

American Journal of Health-System Pharmacy | April 9, 2025 | Volume: 82 | Issue: 18 | Pages: 970-978

10.1093/ajhp/zxaf086 | PMID 40202429 Get It

Abstract Purpose Data regarding the incidence, onset, and management of complex outpatient antimicrobial therapy–induced neutropenia (COIN) are limited, and pharmacist involvement in COIN management has not been reported. This report describes the incidence, onset, and management of COIN at a large academic medical center. Methods This multisite retrospective cohort study examined adult patients undergoing serum laboratory monitoring for antimicrobials over a 4-year period. Patients receiving chemotherapy or immunosuppressants were excluded. Data collected included the antimicrobial regimen, complete blood count, duration of antimicrobial therapy until outcome occurrence, infectious syndrome, type of intervention, outcome, and pharmacist involvement. Logistic regression was used to assess risk factors for COIN incidence. The primary outcome was the incidence of COIN by antimicrobial drug. Results From 4,261 treatment episodes, 161 cases of COIN were identified (3.8% COIN incidence). The most common antimicrobials associated with COIN were intravenous piperacillin/tazobactam, cefepime, and meropenem. The majority of COIN events were attributed to a combination of at least 2 antimicrobials. Piperacillin/tazobactam was significantly associated with higher odds of developing COIN (odds ratio [OR], 1.86; 95% confidence interval [CI], 1.04-3.34; P = 0.038), whereas ertapenem was associated with significantly lower odds of COIN (OR, 0.43; 95% CI, 0.24-0.77; P = 0.005). The median time to neutropenia diagnosis was 22 days (interquartile range, 14-29 days) from the time of inpatient antimicrobial start. Intervention for COIN occurred in 66.5% of cases, with neutrophil count recovering in 96.9% of these patients. Clinical pharmacists initiated 74.8% of interventions. Conclusion COIN can be effectively identified and managed by a multidisciplinary team reviewing routine laboratory monitoring, enabling most patients to safely complete antimicrobial treatment.
Primary Cutaneous Anaplastic Large Cell Lymphoma With TCR‐γδ Expression: A Case Series of Eleven Patients of a Rare Immunophenotypic Variant
Erem, Anna Sarah , Mitteldorf, Christina , Pulitzer, Melissa , Rodríguez-Pinilla, Socorro Marıá , Feldman, Andrew L. , Gru, Alejandro A. , Pulitzer, Melissa , Torres-Cabala, Carlos , Feldman, Andrew L , Gru, Alejandro , Kempf, Werner , Torres‐Cabala, Carlos A. , Pileri, Stefano

Journal of Cutaneous Pathology | April 9, 2025 | Volume: 52 | Issue: 7 | Pages: 487-496

10.1111/cup.14809 | PMID 40202044 Get It

ABSTRACTBackgroundPrimary cutaneous anaplastic large cell lymphoma (pcALCL) and lymphomatoid papulosis (LyP) are indolent CD30‐positive lymphoproliferative disorders that rarely express TCR‐γδ. However, primary cutaneous gamma‐delta T‐cell lymphoma (pcGDTCL), characterized by TCR‐γδ expression on neoplastic cells, is a rare, aggressive cutaneous T‐cell lymphoma with a poor prognosis. Accurate differentiation is essential due to distinct clinical behavior and treatment.MethodsWe identified 11 TCR‐γδ‐positive pcALCL cases from internal and consultation files, verified by two cutaneous lymphoma experts, with clinicopathologic data recorded.ResultsThe median age was 68 years (range 38–95). Most cases presented as a single dermal lesion on the upper extremities. All were ALK‐negative, CD30‐positive (> 90% tumor cells), TCR‐βF1‐negative, and diffusely TCR‐γδ‐positive. CD4−/CD8− (54.5%) and CD4+/CD8− (45.5%) immunophenotypes were observed. CD2 (63.6%) and CD3 (54.5%) were the most common T‐cell antigens. Ulceration, inflammation (both 45.5%), and necrosis (36.4%) were frequent. Angiotropism, angiocentricity, and myxoid stroma appeared in one case; epidermotropism in two. Four of ten tested were DUSP22‐rearranged, and TP63 was negative in all eight tested.ConclusionsMost ALK‐negative TCR‐γδ‐positive pcALCL were CD4−/CD8−, followed by CD4+/CD8−. DUSP22 rearrangement occurred in 40% of cases, similar to reports in typical pcALCL. Its prognosis and the role of DUSP22 are yet to be clarified.
Mechanisms of Gastroesophageal Reflux Post-Roux-en-Y Gastric Bypass: Universal Alteration of the Antireflux Barrier is the Culprit
Annan, Karim Al , Aburumman, Razan Nabeel Mousa, Abedalqader, Tala , Mrad, Rudy , Gala, Khushboo , Brunaldi, Vitor , Ghanem, Omar M. , Dayyeh, Barham K. Abu

Surgical Laparoscopy, Endoscopy & Percutaneous Techniques | April 9, 2025 | Volume: 35 | Issue: 3 | Pages: No page available

10.1097/sle.0000000000001366 | PMID 40202306 Get It

Introduction: Gastroesophageal reflux disease (GERD) symptoms and the use of proton pump inhibitors (PPIs) remain prevalent after Roux-en-Y Gastric Bypass (RYGB), despite it being known to alleviate reflux. The physiological changes behind long-term GERD and hiatal hernia (HH) prevalence post-RYGB are not commonly investigated. Methods: In this consecutive cohort study, we examined patients who underwent RYGB and subsequent upper endoscopy, conducted by an expert bariatric endoscopist. The primary focus was on pouch endoscopic retrosflexion to evaluate the antireflux barrier (ARB). We gathered data encompassing patient demographics, anthropometrics, comorbidities, and findings from esophagogastroduodenoscopy (EGD) at the time of surgery and during follow-up EGD. Results: Our study included a total of 42 patients, predominantly female (97.5%) and White (100%), with an average age of 53.6±10.6 years and a body mass index (BMI) of 32.9±9.4 kg/m 2 . In our findings, all EGDs revealed the presence of a HH of varying sizes. The average HH size was 2.07±0.87 cm. The esophagogastric junction (EGJ) flap was also effaced in all patients with the majority (90.4%, 38 patients) classified as Hill grade IV and a smaller proportion (9.6%, 4 patients) as Hill grade III. Notably, PPI usage increased from the time of surgery to the time of EGD (69.0% vs. 42.9%, P =0.06). Conclusion: This research highlights the high incidence of HH and EGJ flap effacement in patients after RYGB, potentially elucidating the persistence of reflux symptoms, including weakly acidic or alkaline reflux, post-RYGB.
NCCN Guidelines® Insights: Testicular Cancer, Version 2.2025
Lin, Daniel W. , Feldman, Darren R., Aggarwal, Rahul , Drakaki, Alexandra , Eggener, Scott E. , Humphrey, Peter A. , Leuva, Harshraj , Levine, Ellis G., Maughan, Benjamin L. , Reichert, Zachery R. , Rwigema, Jean‐Claude M. , Shah, Sumit, Singla, Nirmish, Sircar, Kanishka , Zhumkhawala, Ali , Sliker, Bailee , Gilligan, Timothy D. , Adra, Nabil , Bagrodia, Aditya , Yamoah, Kosj , Chandrasekar, Thenappan , Costa, Daniel Nobrega da , Drakaki, Alexandra , Emamekhoo, Hamid , Geynisman, Daniel M. , Graham, Laura , Luckenbaugh, Amy N. , McGregor, Bradley A. , Monk, Paul , Picus, Joel , Pierorazio, Phillip , Rais‐Bahrami, Soroush , Saylor, Philip J. , Shah, Ankeet , Shah, Sumit, VanderWeele, David James , Montgomery, Sarah E.

Journal of the National Comprehensive Cancer Network | April 9, 2025 | Volume: 23 | Issue: 4 | Pages: No page available

10.6004/jnccn.2025.0018 | PMID 40203876 Get It

The NCCN Guidelines for Testicular Cancer provide recommendations for the multidisciplinary approach to the diagnostic workup, treatment, and follow-up for testicular germ cell tumors, including both seminoma and nonseminoma. These NCCN Guidelines Insights discuss the current treatment recommendations and supporting clinical data for seminomas as presented in Version 2.2025 of the NCCN Guidelines for Testicular Cancer.
Bone Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Biermann, J. Sybil, Boles, Sarah G , Brigman, Brian E. , Callan, Alexandra K. , Cranmer, Lee D., Davis, Jessica , Donnelly, Eric D. , Ferguson, Michael J. , Graham, Ann, Groundland, John , Hess, Matthew, Hiniker, Susan M. , Hoover‐Regan, Margo , Jonard, Brandon , Lindskog, Dieter M. , Mayerson, Joel , McGarry, Sean V., Olson, Daniel J. , Rose, Peter S. , Santana, Victor M. , Satcher, Robert L. , Schwartz, Herbert S. , Shulman, Rebecca M. , Wustrack, Rosanna , Yoon, Janet, Hang, Lisa E., Jones, Frankie, Sansone, Nicholas, Lyons, Megan , Hirbe, Angela C. , Ahlawat, Shivani , Bernthal, Nicholas M , Binitie, Odion , Cipriano, Cara A. , Cranmer, Lee D. , Graham, Ann, Hess, Matthew, Hornick, Jason L. , Kuechle, Joseph , Morris, Carol D. , Thorpe, Steven W. , Wilky, Breelyn A , Lyons, Megan

Journal of the National Comprehensive Cancer Network | April 9, 2025 | Volume: 23 | Issue: 4 | Pages: No page available

10.6004/jnccn.2025.0017 | PMID 40203873 Get It

Ewing sarcoma and osteosarcoma constitute 36% of all primary bone cancers. However, these 2 subtypes represent the most commonly diagnosed bone cancer types in the pediatric and adolescent population. Although still largely unknown, certain genetic mutations, rearrangements, and/or predisposition syndromes likely play a role in the pathogenesis of bone cancer. Osteosarcoma may also develop as a direct result of the long-term side effects of radiation therapy. With the implementation of a multimodality approach to treatment, including multiagent neoadjuvant and adjuvant chemotherapy regimens, targeted therapy options, surgery, and radiation, individuals with Ewing sarcoma and osteosarcoma are showing higher cure rates and improved overall survival. The NCCN Guidelines for Bone Cancer provide a consensus and evidence-based framework for the workup, management, and surveillance of local and recurrent/metastatic disease.
Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements
Nakazawa, Seshiru , Pecci, Federica , Odintsov, Igor , Gazgalis, Dimitris , Gottlieb, Felix H. , Ricciuti, Biagio , Zullo, Lodovica , Alessi, Joao V. , Federico, Alessandro Di , Aldea, Mihaela , Garbo, Edoardo , Saini, Arushi , Jiang, Jie , Baldacci, Simon , Makarem, Maisam , Locquet, Marie-Anaïs , Haradon, Danielle , Italiano, Antoîne , Lavaud, Pernelle , Vasseur, Damien , Planchard, David , Watanabe, Y., Mahran, Hoda A., Niu, Jiaxin , Swan, Leong Swan, Tay, Kevin , Kizilbash, Sani H. , Yu, Kin-Hung P. , Zhang, Xiaoling , Chen, Pan , Sangem, Mythili, Che, Jianwei , Sholl, Lynette M. , Jänne, Pasi A. , Di Federico, Alessandro , Gandhi, Malini M , Saini, Arushi , Feng, William W , Jiang, Jie , Baldacci, Simon , Facchinetti, Francesco , Makarem, Maisam , Locquet, Marie-Anaïs , Haratani, Koji , Haradon, Danielle , Besse, Benjamin , Italiano, Antoine , Remon, Jordi , Lavaud, Pernelle , Vasseur, Damien , Planchard, David , Sato, Yusuke , Watanabe, Yukako , Owen, Scott , Cortot, Alexis B , Mahran, Hoda , Forster, Martin D , Niu, Jiaxin , Tomasini, Pascale , Leong, Swan Swan , Tay, Kevin , Esteban, Emilio , Minchom, Anna , Kizilbash, Sani H , Cruz-Correa, Marcia , Yu, Kin-Hung Peony , Zhang, Xiaoling , Chen, Pan , Sangem, Mythili , Che, Jianwei , Sholl, Lynette , Jänne, Pasi A , Awad, Mark M , Odintsov, Igor , Ricciuti, Biagio , Aldea, Mihaela , Garbo, Edoardo , Gazgalis, Dimitris , Besse, Benjamin , Cortot, Alexis B. , Tomasini, Pascale , Cruz‐Correa, Marcia , Awad, Mark M.

Cancer Discovery | April 9, 2025 | Volume: 15 | Issue: 6 | Pages: 1129-1140

10.1158/2159-8290.cd-24-1726 | PMID 40202082 Get It

Abstract Oncogenic translocations involving the MET gene have been reported in several cancer types, but detailed clinicogenomic characterization of these cancers is not well defined. In addition, prospective clinical trials evaluating the antitumor activity of MET inhibitors in MET rearrangement–positive cancers are limited. In this study, in a pan-cancer analysis of >46,000 solid tumors with comprehensive genomic profiling, we identified oncogenic MET rearrangements in ∼0.04% of cancers. Preliminary analysis from a phase II clinical trial of the type I MET tyrosine kinase inhibitor (TKI) vebreltinib in MET fusion–positive solid tumors demonstrated an objective response rate of 50% and disease control rate of 79%, with antitumor activity seen in diverse cancer types, including lung adenocarcinoma and intrahepatic cholangiocarcinoma, among others. Similar to MET exon 14–altered lung cancer, secondary mutations in the kinase domain can confer resistance to MET TKIs in MET fusion–positive cancers. Overall, these data categorize MET rearrangements as actionable targets in solid tumors. Significance: MET rearrangement–positive cancers are not well-characterized, and optimal treatment strategies are yet to be defined. Through comprehensive genomic analysis, preclinical modeling, and preliminary results of a phase II clinical trial, we demonstrate that MET fusions are a unique molecular subtype of cancers targetable with vebreltinib, a TKI in development.